IP Library › Granted Patent US 12,496,468
Granted Patent B2
US 12,496,468 · App. 18/505,694 · Granted Dec 16, 2025

Irradiation method and system

Inventors: Mitra Safavi-Naeini (Stanwell Park, AU); Andrew Stephen Chacon (Minto, AU)
Assignees: Australian Nuclear Science and Technology Organisation; University of Wollongong
A61N5/1078A61N5/1065G21K5/04H05H7/10H05H13/04H05H13/10A61N2005/1034A61N2005/1087A61N2005/109A61N2005/1098
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,496,468
App. No.
18/505,694
Granted
Dec 16, 2025
Kind
B2
Abstract

An irradiation method and system for irradiating a target volume, the method comprising: providing thermal neutron absorbing nuclides (such as in the form of a high neutron cross-section agent) at the target volume; and producing neutrons by irradiating nuclei in or adjacent to the target volume with a beam of particles consisting of any one or more of protons, deuterons, tritons and heavy ions, thereby prompting production of the neutrons through non-elastic collisions between the atoms in the path of the beam (including the target) and the particles. The neutron absorbing nuclides absorb neutrons produced in the non-elastic collisions, thereby producing capture products or fragments that irradiate the target volume.

Claims (68)

1 . An irradiation method for irradiating a target volume of a subject, the method comprising:

providing thermal neutron absorbing nuclides in or adjacent to the target volume of the subject; and

producing neutrons by irradiating nuclei of the subject with a beam of particles consisting of any one or more of deuterons, tritons, 4 He, 10 C, 11 C, 12 C, 15 O, 16 O and heavy ions, thereby prompting production of the neutrons in the subject through non-elastic collisions within the subject between the nuclei and the particles;

wherein the thermal neutron absorbing nuclides absorb neutrons produced in the non-elastic collisions, thereby producing capture products or fragments that irradiate the target volume.

2 . The method as claimed in claim 1 , further comprising configuring the beam of particles so as to also irradiate the target volume.

3 . The method as claimed in claim 1 , further comprising:

a) providing the thermal neutron absorbing nuclides in the form of a composition comprising 10 B or 157 Gd; or

b) providing the thermal neutron absorbing nuclides in the form of a composition comprising 10 B or 157 Gd, wherein the composition is preferentially absorbed by a malignant target tissue.

4 . The method as claimed in claim 1 , wherein the capture products or fragments comprise energetic charged particles of high relative biological effectiveness or other energetic charged particles.

5 . The method as claimed in claim 1 , wherein the beam of particles:

a) irradiates matter along its path in a spot scanning manner, a uniform scanning manner, a fast scanning manner, raster scanning manner, or a passively scattered manner; and/or

b) has a Bragg peak that is outside the subject.

6 . A method of irradiating biological tissue, the method comprising irradiating a target volume according to the method of claim 1 , wherein the target volume includes the biological tissue.

7 . A method of inhibiting growth of any one or more of a tumour, satellite lesion or metastatic lesion of a subject, the method comprising:

dosing the subject in or adjacent to the tumour, satellite lesion or metastatic lesion with a composition comprising thermal neutron absorbing nuclides; and

irradiating nuclei of the subject with a beam of particles consisting of any one or more of deuterons, tritons, 4 He, 10 C, 11 C, 12 C, 15 O, 16 O and heavy ions, thereby producing neutrons in the subject through non-elastic collisions within the subject between the nuclei and the particles;

wherein the thermal neutron absorbing nuclides absorb neutrons produced in the non-elastic collisions, thereby producing capture products or fragments that irradiate the tumour, satellite lesion or metastatic lesion.

8 . The method as claimed in claim 7 , further comprising:

a) providing the thermal neutron absorbing nuclides in the form of a composition comprising 10 B or 157 Gd; or

b) providing the thermal neutron absorbing nuclides in the form of a composition comprising 10 B or 157 Gd, wherein the composition is preferentially absorbed by the tumour, satellite lesion or intracranial metastatic lesion.

9 . The method as claimed in claim 7 , wherein the capture products or fragments comprise energetic charged particles of high relative biological effectiveness or other energetic charged particles.

10 . The method as claimed in claim 7 , wherein said beam:

a) irradiates matter along its path in a spot scanning manner, a uniform scanning manner, a fast scanning manner, raster scanning manner, or a passively scattered manner; and/or

b) has a Bragg peak that is outside the subject.

11 . A computer-implemented method of determining parameters for particle therapy of a subject, the method comprising:

modelling or simulating, based on a set of default or selected parameters:

a) irradiation of nuclei of the subject with a beam of primary particles consisting of any one or more of deuterons, tritons, 4 He, 1 C, 11 C, 12 C, 15 O, 16 O and heavy ions;

b) production of neutrons in the subject through non-elastic collisions within the subject between the nuclei in or adjacent to the target volume and the primary particles; and

c) production of capture products or fragments released as a result of the neutron capture and nuclear reactions between at least one high thermal neutron cross section agent located in or adjacent to a target volume of the subject and the neutrons produced from the non-elastic collisions within the subject between the nuclei and the primary particles;

determining a difference between the production of the capture products or fragments with either (i) a predetermined template or desired production of the capture products or fragments, or (ii) empirical reaction validation data; and

generating a modified set of parameters according to the difference.

12 . The method as claimed in claim 11 , wherein the modelling or simulating further comprises:

modelling irradiation of a tumour or a portion thereof, one or more satellite lesions or one or more metastatic lesions, or other tissue, within or adjacent to the target volume by the capture products or fragments; or

modelling a composition comprising the thermal neutron absorbing nuclides located in the target volume; or

modelling or simulating the target volume as PMMA (poly(methyl methacrylate)) or other tissue equivalent material.

13 . The method as claimed in claim 11 , wherein the parameters comprise any one or more of:

i) duration of the irradiation;

ii) composition of the beam;

iii) energy of the particles of the beam;

iv) peak radiobiological effectiveness of the particles of the beam;

v) physical dose deposition of the particles of the beam;

vi) the composition that comprises thermal neutron absorbing nuclides;

vii) concentration of the composition that comprises thermal neutron absorbing nuclides;

viii) spatial distribution of the composition that comprises thermal neutron absorbing nuclides;

ix) fluence of the neutrons produced in the subject through the non-elastic collisions;

x) the distribution of the thermalised neutrons;

xi) target volume position relative to the beam; or

xii) ion specific radiobiological efficacy.

14 . The method as claimed in claim 11 , further comprising modelling or simulating the beam so as:

a) to irradiate matter along its path in a spot scanning manner, a uniform scanning manner, a fast scanning manner, raster scanning manner, or a passively scattered manner; and/or

b) to have a Bragg peak that is outside the subject.

15 . A non-transitory computer-readable medium, comprising computer software configured to, when executed by one or more processors, implement the method of determining parameters for particle therapy according to claim 11 .

16 . A control system for controlling an irradiation system, wherein:

the irradiation system provides a particle beam of accelerated particles comprising any one or more of any one or more of deuterons, tritons, 4 He, 10 C, 11 C, 12 C, 15 O, 16 O and heavy ions; and

the control system includes or is configured to access an irradiation program for implementing a predetermined irradiation of a target volume of a subject, the predetermined irradiation comprising:

irradiating nuclei of the subject with the particle beam, thereby prompting production of neutrons in the subject through non-elastic collisions within the subject between the nuclei and the particles, whereby thermal neutron absorbing nuclides provided before irradiation at or adjacent to the target volume absorb neutrons produced in the non-elastic collisions, thereby producing capture products or fragments that irradiate the target volume.

17 . The control system as claimed in claim 16 , comprising:

a particle supply controller configured to control a particle source of the irradiation system, the particle source supplying the particles;

an accelerator controller configured to control an accelerator of the irradiation system, the accelerator providing the particle beam by accelerating the particles;

a beam steerer for controlling one or more beam steering units configured to direct the particle beam; and

an extraction controller for controlling extraction of the accelerated particles from the accelerator.

18 . An irradiation system, comprising:

a particle source for supplying primary particles comprising any one or more of deuterons, tritons, 4 He, 10 C, 11 C, 12 C, 15 O, 16 O and heavy ions;

an accelerator for providing a particle beam by accelerating the particles;

an extraction beamline for extracting the particle beam from the accelerator;

one or more beam steering units configured to direct the particle beam; and

a control system as claimed in claim 16 .

19 . The irradiation system as claimed in claim 18 , wherein the irradiation program, or a set of parameters employed thereby, is adapted or personalized for a specific target volume or subject.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2025
From: SAFAVI-NAEINI, MITRA; CHACON, ANDREW STEPHEN
To: AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION; UNIVERSITY OF WOLLONGONG
Reel/Frame 071896/0798 →
Priority Claims (1)
AU 2017903739 · Sep 14, 2017 · national
Continuity (2)
Continuation 16644368
Related Publication 20240075319A1 · Mar 7, 2024
References Cited (86)
US 7579603B2 · Birgy · 2009 [cited by examiner]
US 9636525B1 · Sahadevan · 2017 [cited by applicant]
US 10004805B2 · Chen · 2018 [cited by examiner]
US 11850449B2 · Safavi-Naeini et al. · 2023 [cited by applicant]
US 20070108922A1 · Amaldi · 2007 [cited by applicant]
US 20130066135A1 · Rosa · 2013 [cited by examiner]
US 20140100409A1 · Kime · 2014 [cited by examiner]
US 20160074512A1 · Chen · 2016 [cited by applicant]
US 20170062086A1 · Park, Jr. · 2017 [cited by examiner]
US 20180161602A1 · Kawrykow et al. · 2018 [cited by applicant]
US 20180247452A1 · Liu et al. · 2018 [cited by applicant]
US 20200197730A1 · Safavi-Naeini et al. · 2020 [cited by applicant]
CN 104511096A · 2015 [cited by applicant]
CN 106474634A · 2017 [cited by applicant]
CN 106955427A · 2017 [cited by examiner]
EP 1658878A1 · 2006 [cited by applicant]
EP 1895819A1 · 2006 [cited by applicant]
EP 2979728A1 · 2016 [cited by applicant]
EP 3133905A1 · 2017 [cited by applicant]
JP 201421078A · 2014 [cited by applicant]
JP 201796672A · 2017 [cited by applicant]
WO WO0015298A1 · 2000 [cited by applicant]
Agostinelli, S. et al., “Geant4-a simulation toolkit” Nuclear Instruments and Methods in Physics Research, 2003, pp. 250-303, vol. 506. [cited by applicant]
Alkins, Ryan D. et al., “Enhancing drug delivery for boron neutron capture therapy of brain tumors with focused ultrasound” Neuro-Oncology, 2013, pp. 1225-1235, vol. 15, No. 9. [cited by applicant]
Allison, J. et al., “Geant4 Developments and Applications” IEEE Transactions on Nuclear Science, Feb. 2006, pp. 270-278, vol. 53, No. 1. [cited by applicant]
Arcangeli, Stefano et al., ““Hit the primary”: A paradigm shift in the treatment of metastatic prostate cancer?” Critical Reviews in Oncology/Hematology, 2016, pp. 231-237, vol. 97. [cited by applicant]
Barth, Rolf F. et al., “Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects” Clin Cancer Res., 2005, pp. 3987-4002, vol. 11. [cited by applicant]
Barth, Rolf F. et al., “Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer” Radiation Oncology, 2012, pp. 1-21, vol. 7, No. 146. [cited by applicant]
Battistoni, G. et al., “Nuclear physics and particle therapy” Advances in Physics: X, 2016, pp. 661-686, vol. 1, No. 4. [cited by applicant]
Blanchard, Pierre et al., “Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort… [cited by applicant]
Capala, J. et al., “A Treatment Planning Comparison of BPA- or BSH-based BNCT of Malignant Gliomas” Tech. Rep. BNL-64626, Medical Department, Brookhaven National Laboratories, 1996. [cited by applicant]
Cerullo, N. et al., “Progress in the use of gadolinium for NCT” Applied Radiation and Isotopes, 2009, pp. S157-S160, vol. 67. [cited by applicant]
Coderre, Jeffrey A. et al., “The Radiation Biology of Boron Neutron Capture Therapy” Radiation Research, Jan. 1999, pp. 1-18, vol. 151, No. 1. [cited by applicant]
Coderre, Jeffrey A. et al., “Boron Neutron Capture Therapy: Cellular Targeting of High Linear Energy Transfer Radiation” Technology in Cancer Research & Treatment, Oct. 2003, pp. 355-375, vol. 2, No. 5. [cited by applicant]
Crane, Christopher H. “Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer” Journal of Radiation Research, 2016, pp. i53-i57, vol. 57, No. S1. [cited by applicant]
De Stasio, Gelsomina et al., “Gadolinium in Human Glioblastoma Cells for Gadolinium Neutron Capture Therapy” Cancer Research, May 2001, pp. 4272-4277, vol. 61. [cited by applicant]
De Stasio, Gelsomina et al., “Motexafin-GadoliniumTaken Up In vitro by at Least 90% of Glioblastoma Cell Nuclei” Clin Cancer Res, Jan. 2006, pp. 206-213, vol. 12, No. 1. [cited by applicant]
Diaz, Aidnag Z. et al., “Assessment of the results from the phase Fll boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view” Journal of Neuro-Oncology, 2003, pp. 101… [cited by applicant]
Durante, Marco et al., “Nuclear physics in particle therapy: a review” Reports on Progress in Physics, 2016, pp. 1-59, vol. 79, No. 096702. [cited by applicant]
Durante, Marco et al., “Charged-particle therapy in cancer: clinical uses and future perspectives” Nature Reviews—Clinical Oncology, Aug. 2017, pp. 483-495, vol. 14. [cited by applicant]
Fairlie, Ian et al., “RBE and wR values of Auger emitters and low-range beta emitters with particular reference to tritium” Journal of Radiological Protection, 2007, pp. 157-168, vol. 27. [cited by applicant]
Forouzannia, Afshin et al., “Motexafin gadolinium: a novel radiosensitizer for brain tumors” Expert Rev. Anticancer Ther., 2007, pp. 785-794, vol. 7, No. 6. [cited by applicant]
Gavin, Patrick R. et al., “Large Animal Normal Tissue Tolerance with Boron Neutron Capture” Int. J. Radiation Oncology Biol. Phys., 1994, pp. 1099-1106, vol. 28, No. 5. [cited by applicant]
Gomez-Iturriaga, Alfonso et al., “Incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: multicenter prospective observational study” BMC Palliative Care, 2015, pp. 1-7, vol. 14, No. … [cited by applicant]
González, Elizabeth Musacchio et al., “An accelerator-based Boron Neutron Capture Therapy (BNCT) facility based on the 7Li(p,n)7Be” Nuclear Instruments and Methods in Physics Research, 2017, pp. 148-151, vol. A865. [cited by applicant]
Grantzau, Trine et al., “Risk of second non-breast cancer after radiotherapy for breast cancer: A systematic review and meta-analysis of 762,468 patients” Radiotherapy and Oncology, 2015, pp. 56-65, vol. 114. [cited by applicant]
Hong, Theodore S. et al., “Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma” Jour… [cited by applicant]
Hopewell, J.W. et al., “Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: An assessment of clinical potential” Applied Radiation and Isotopes, 2011, pp. 1737-1740, vol. 69. [cited by applicant]
Humm, John L. et al., “Dosimtery of Auger-electron-emitting radionuclides: Report No. 3 of AAPM Nuclear Medicine Task Group No. 6a)” Med. Phys., Dec. 1994, pp. 1901-1915, vol. 21, No. 12. [cited by applicant]
IAEA-TECDOC-1223 “Current status of neutron capture therapy” International Atomic Energy Agency, May 2001. [cited by applicant]
IAEA Technical Reports Series No. 461 “Relative Biological Effectiveness in lon Beam Therapy” International Atomic Energy Agency, 2008. [cited by applicant]
Ichikawa, Hideki et al., “Gadolinium-loaded chitosan nanoparticles for neutron-capture therapy: Influence of micrometric properties of the nanoparticles on tumor-killing effect” Applied Radiation and Isotopes, 2014, pp.… [cited by applicant]
Joensuu, Heikki et al., “Boron neutron capture therapy of brain tumors: clinical trials at the Finnish facility using boronophenylalanine” Journal of Neuro-Oncology, 2003, pp. 123-134, vol. 62. [cited by applicant]
Karg, Juergen et al., “The Monte Carlo code MCPTV-Monte Carlo dose calculation in radiation therapy with carbon ions” Phys. Med. Biol., 2010, pp. 3917-3936, vol. 55. [cited by applicant]
Kasatov, D. et al., “The accelerator neutron source for boron neutron capture therapy” Journal of Physics: Conference Series, 2016, pp. 1-6, vol. 769, No. 012064. [cited by applicant]
Laine, Aaron Michael et al., “The Role of Hypofractionated Radiation Therapy with Photons, Protons, and Heavy lons for Treating Extracranial Lesions” Frontiers in Oncology, Jan. 2016, pp. 1-14, vol. 5, Article 302. [cited by applicant]
Le, Uyen M. et al., “Long-circulating gadolinium-encapsulated liposomes for potential application in tumor neutron capture therapy” International Journal of Pharmaceutics, 2006, pp. 105-112, vol. 312. [cited by applicant]
Liauw, Stanley L. et al., “New paradigms and future challenges in Radiation Oncology: An Update of Biological Targets and Technology” Science Translational Medicine, Feb. 2013, pp. 1-32, vol. 5, No. 173. [cited by applicant]
Luderer, Micah John et al., “Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy” Pharm Res, 2015, pp. 2824-2836, vol. 32. [cited by applicant]
Meyers, Christina A. et al., “Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial” Journal of Cl… [cited by applicant]
Michiue, Hiroyuki et al., “The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide” Biomaterials, 2014, pp. 3396-3405, vol. 35. [cited by applicant]
Miyatake, Shin-Ichi et al., “Boron Neutron Capture Therapy for Malignant Brain Tumors” Neurol Med Chir, 2016, pp. 361-371, vol. 56. [cited by applicant]
Morris, GM et al., “Boron microlocalization in oral mucosal tissue: implications for boron neutron capture therapy” British Journal of Cancer, 2000, pp. 1764-1771, vol. 82, No. 11. [cited by applicant]
Morrison, Daniel E. et al., “High mitochondrial accumulation of new gadolinium(III) agents within tumour cells” Chem. Commun., 2014, pp. 2252-2254, vol. 50. [cited by applicant]
Murray, Louise et al., “Second primary cancers after radiation for prostate cancer: A systematic review of the clinical data and impact of treatment technique” Radiotherapy and Oncology, 2014, pp. 213-228, vol. 110. [cited by applicant]
Nakamura, Hiroyuki et al., “Development of High Boron Content Liposomes and Their Promising Antitumor Effect for Neutron Capture Therapy” Yakugaku Zasshi, 2013, pp. 1297-1306, vol. 133, No. 12. [cited by applicant]
Nakamura, Hiroyuki et al., “Antitumor effect of boron nitride nanotubes in combination with thermal neutron irradiation on BNCT” Bioorganic & Medicinal Chemistry Letters, 2015, pp. 172-174, vol. 25. [cited by applicant]
Park, Seo Hyun et al., “Basics of particle therapy I: physics” Radiation Oncology Journal, 2011, pp. 135-146, vol. 29, No. 3. [cited by applicant]
Peters, Tanja et al., “Cellular uptake and in vitro antitumor efficacy of composite liposomes for neutron capture therapy” Radiation Oncology, 2015, pp. 1-13, vol. 10, No. 52. [cited by applicant]
Sauerwein, Wolfgang A.G. et al., “Neutron Capture Therapy—Principles and Applications” 2012. [cited by applicant]
Supplementary European Search Report for EP 18856248 dated Apr. 20, 2021. [cited by applicant]
Suzuki, Minoru et al., “The Effects of Boron Neutron Capture Therapy on Liver Tumors and Normal Hepatocytes in Mice” Jpn. J. Cancer Res., Oct. 2000, pp. 1058-1064, vol. 91. [cited by applicant]
Suzuki, Minoru et al., “Biodistribution of 10B in a rat liver tumor model following intra-arterial administration of sodium borocaptate (BSH) / degradable starch microspheres (DSM) emulsion” Applied Radiation and Isotop… [cited by applicant]
Suzuki, Minoru et al., “A Preliminary Experimental Study of Boron Neutron Capture Therapy for Malignant Tumors Spreading in Thoracic Cavity” Jpn J Clin Oncol, 2007, pp. 245-249, vol. 37, No. 4. [cited by applicant]
Thomas, Sayana Rachel et al., “Motexafin gadolinium: a promising radiation sensitizer in brain metastasis” Expert Opinion on Drug Discovery, 2011, pp. 195-203, vol. 6, No. 2. [cited by applicant]
Tietze, Rainer et al., “Boron containing magnetic nanoparticles for neutron capture therapy—an innovative approach for specifically targeting tumors” Applied Radiation and Isotopes, 2015, pp. 151-155, vol. 106. [cited by applicant]
Tokumitsu, Hiroyuki et al., “Gadolinium neutron-capture therapy using novel gadopentetic acid-chitosan complex nanoparticles: in vivo growth suppression of experimental melanoma solid tumor” Cancer Letters, 2000, pp. 17… [cited by applicant]
Xinchen, Sun et al., “IV. Proton and heavy ion therapy—1. Physical and Biological Characteristics of Proton Rays,” Oncology Radiation Therapy Technology, Sep. 30, 2015. [cited by applicant]
Wambersie, André et al., “A Challenge for High-Precision Radiation Therapy: The Case for Hadrons” Strahlenther Onkol, 1999, pp. 122-128, vol. 175, Suppl. 2. [cited by applicant]
Yoshioka, M. “Review of Accelerator-based Boron Neutron Capture Therapy Machines” Proceedings of IPAC2016, Busan, Korea—OIST, Okinawa Institute of Science and Technology Graduate University, Onna-son, Japan, pp. 3171-31… [cited by applicant]
Zamenhof, R. et al., “Treatment Planning for Neutron Capture Therapy of Glioblastoma Multiforme Using an Epithermal Neutron Beam from the MITR-II Research Reactor and Monte Carlo Simulation” Progress in Neutron Capture … [cited by applicant]
Zeitlin, Cary et al., “The Role of Nuclear Fragmentation in Particle Therapy and Space Radiation Protection” Frontiers in Oncology, Mar. 2016, pp. 1-13, vol. 6, Article 65. [cited by applicant]
Second Office Action for CN 201880069367.5 issued Mar. 15, 2022. [cited by applicant]
International Search Report for PCT/AU2018/051006 dated Nov. 26, 2018. [cited by applicant]
Japanese Office Action for JP 2023-194786 dated Dec. 16, 2024. [cited by applicant]
Office Action for CN 201880069367.5 dated Sep. 18, 2021. [cited by applicant]